Pay TV: Get Ready for Direct to Consumer Advertising User Fees
This article was originally published in RPM Report
Executive Summary
FDA is proposing that drug sponsors assume responsibility for testing proprietary trademarks for potential medication errors before they are reviewed by the agency. That -- along with performance goals tied to user fee dollars -- should help speed up the review of proposed brand names.
You may also be interested in...
The New Era in DTC: FDA Plans New Fees, Fines-and Creative Advice
The new FDA law marks a turning point in the relatively short history of direct-to-consumer broadcast ads. Sponsors have preserved the right to advertise, but will have to get used to following FDA's schedule-and taking FDA's advice.
Go Ahead and Advertise--If You Dare
Congress agrees with the pharmaceutical industry that the right to advertise new drugs is protected by the First Amendment. But pharma companies have a long way to go to prove to their critics that it is the right thing to do.
The Power of the Purse: FDA Seeks More Money, Not More Authority
Congress can't wait to shower FDA with more regulatory authority, especially in the area of drug safety. But unless Capitol Hill can puts its money where its mouth is, expanding FDA's mission will only send the agency deeper into a fiscal crisis -- and leave industry worse off as a result. An underfunded agency leaves officials scrambling to complete day-to-day activities -- and less time to on activities to further drug development, like nanotechnology and the Critical Path initiative.